Dogwood Therapeutics, Inc. Announces Conversion of Existing $19.5M in Debt to Equity, Strengthening Balance Sheet Moving Forward
ATLANTA, March 12, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) ('Dogwood' or the 'Company'), a development-stage biopharmaceutical company focused on advancing first-in-class, non-opioid, treatments for chronic and acute pain, announces that its largest shareholder, CK Life Sciences Int'l., (Holdings), Inc. ('CKLS') has agreed, through its wholly-owned subsidiary, Conjoint Inc. ('Conjoint'), to assign to the Company all outstanding indebtedness under the previously existing $19.5 million Loan Agreement plus accrued interest in exchange for 284.2638 shares of preferred equity of the Company, effective today.
'We believe the decision by CKLS to exchange the outstanding loan amounts for equity in the Company is anchored to its conviction in Halneuron®, NaV 1.7 as a priority target for reducing pain. The conversion further underscores its confidence in the Dogwood management teams' ability to execute the Halneuron® Phase 2b chemotherapy-induced neuropathic pain ('CINP') program,' said Greg Duncan, Dogwood's Chairman and Chief Executive Officer. 'This agreement enables us to remove all existing debt from our balance sheet, which, combined with the potential for Halneuron® to be the first FDA approved therapy to treat CINP, we believe makes us a more attractive investment opportunity moving forward.'
The strategic financing, initially provided by CKLS in October 2024, ensures the Company has sufficient capital to recruit patients through a planned interim assessment of its ongoing Phase 2b CINP trial in Q4 of this year without the burden of making debt payments as originally structured. Dosing of the first patient in its Phase 2b clinical trial, referred to as the HALT-CINP (Halneuron® Treatment of Chemotherapy-Induced Neuropathic Pain) trial, is anticipated in the near term.
Pursuant to the Debt Exchange and Cancellation Agreement entered into between Conjoint and the Company on March 12, 2025, the principal amount of all loans made to the Company under the Loan Agreement, along with accrued interest through March 12, 2025, will be deemed repaid by the Company and all of the Company's obligations with respect to the principal amount and accrued interest will be satisfied in full and cancelled. In exchange, the Company has agreed to issue to Conjoint 284.2638 shares of Series A-1 Non-Voting Convertible Preferred Stock, par value $0.0001 per share ('A-1 Preferred Stock'). Each share of A-1 Preferred Stock will be convertible into 10,000 shares of the Company's common stock, subject to and contingent upon approval of the Company's stockholders and relevant Nasdaq rules and regulations. The terms of the A-1 Preferred Stock are substantially the same as the Company's Series A Non-Voting Convertible Preferred Stock, except that the terms of the A-1 Preferred Stock do not provide for any cash settlement or dividend rights.
Halneuron® is a first-in-class, NaV 1.7 specific voltage gated sodium channel inhibitor being developed as an alternative to chronic pain treatment with opioids. Patients treated with Halneuron® demonstrated a statistically significant reduction in cancer-related pain in a previous Phase 2 clinical trial with an acceptable safety profile. Halneuron® has been evaluated in over 700 patients in a series of Phase 1 and Phase 2 studies and shows no signs of addiction potential.
About Dogwood Therapeutics
Dogwood Therapeutics (Nasdaq: DWTX) is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and fatigue-related disorders. The Dogwood research pipeline includes two separate mechanistic platforms with a non-opioid analgesic program and an antiviral program. The proprietary, non-opioid, NaV 1.7 analgesic program is centered on our lead development candidate, Halneuron®, which is a highly specific voltage-gated sodium channel modulator, a mechanism known to be effective for reducing pain transmission. In clinical studies, Halneuron® treatment has demonstrated pain reduction in pain related to general cancer and in pain related to chronic chemotherapy-induced neuropathic pain ('CINP'). Interim data from the forthcoming Halneuron® Phase 2 CINP study are expected in Q4 of 2025.
Dogwood's antiviral program includes IMC-1 and IMC-2, which are novel, proprietary, fixed-dose combinations of anti-herpes antivirals and the anti-inflammatory agent celecoxib. These combination antiviral approaches are being applied to the treatment of illnesses believed to be related to reactivation of previously dormant herpesviruses, including fibromyalgia ('FM') and Long-COVID ('LC'). IMC-1 is poised to progress into Phase 3 development as a treatment for FM and is the focus of external partnership activities. IMC-2 has been assessed in both active control and double-blind, placebo-controlled clinical trials and, in both cases, demonstrated successful reduction of the fatigue associated with LC. The company has reached an agreement with FDA on using reduction in fatigue as the primary endpoint for future LC research and is currently planning to advance IMC-2 into Phase 2b research.
For more information, please visit www.dwtx.com.
Follow Dogwood Therapeutics
Email Alerts: https://ir.dwtx.com/resources/email-alerts
LinkedIn: https://www.linkedin.com/company/dogwoodther/
Twitter: https://twitter.com/dogwoodther
Facebook: https://www.facebook.com/dogwoodther
Forward-Looking Statements
Statements in this press release contain 'forward-looking statements,' within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as 'anticipate,' 'believe,' 'contemplate,' 'could,' 'estimate,' 'expect,' 'intend,' 'seek,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'suggest,' 'target,' 'aim,' 'should,' "will,' 'would,' or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Dogwood's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the completion, timing and results of current and future clinical studies relating to Dogwood's product candidates. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled 'Risk Factors' in the Amended Annual Report on Form 10-K/A for the year ended December 31, 2023 and the Company's quarterly report on Form 10-Q for the quarterly period ended September 30, 2024, which are filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Dogwood undertakes no duty to update such information except as required under applicable law.
Investor Relations:CORE IR (516) 222-2560IR@dwtx.comSign in to access your portfolio
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
TPI Composites, Inc. Advances Chapter 11 Process with Court Approval of First-Day Motions
SCOTTSDALE, Ariz., Aug. 13, 2025 (GLOBE NEWSWIRE) -- TPI Composites, Inc. (NASDAQ: TPIC) together with its domestic subsidiaries (collectively, 'TPI' or the 'Company') announced today that the U.S. Bankruptcy Court for the Southern District of Texas (the 'Bankruptcy Court') approved all first-day motions filed by the Company in connection with its voluntary chapter 11 proceedings. The approvals provide the Company with the operational flexibility and liquidity necessary to continue normal business operations during the chapter 11 process. Key motions approved include, interim approval for debtor-in-possession financing from its senior secured lenders of up to $82.5 million, the continuation of employee wages and benefits, maintenance of cash management systems, and the authority to pay certain prepetition obligations critical to ongoing operations. 'Our priority is to maintain stability and support for our employees, customers, and partners during this process,' said Bill Siwek, Chief Executive Officer of TPI. 'The court's approval of these first-day motions allows us to focus on executing our strategic initiatives to strengthen the Company for the long term.' Additional Information Additional information regarding the Company's court-supervised process is available at Court filings and other information related to the proceedings are available on a separate website administrated by the Company's claims agent, Kroll, at by calling Kroll representatives at (877) 280-2696 within the U.S. & Canada (or +1 (646) 290-7082 internationally for calls originating outside of the U.S.); or by sending an email to TPIinfo@ About TPI TPI Composites, Inc. is a global company focused on innovative and sustainable solutions to decarbonize and electrify the world. TPI delivers high-quality, costeffective composite solutions through long-term relationships with leading OEMs in the wind markets. TPI is headquartered in Scottsdale, Arizona and operates factories in the U.S., Mexico, Türkiye and India. TPI operates additional engineering development centers in Denmark and Germany and global service training centers in the U.S. and Spain. Forward-Looking Statements This release contains forward-looking statements made pursuant to safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward looking statements include statements, among other things, concerning: the adoption, implementation and consummation of a Chapter 11 plan of reorganization; the commencement of Chapter 11 proceedings in U.S. bankruptcy court; growth of the wind energy and electric vehicle markets and our addressable markets for our products and services; effects on our financial statements and our financial outlook; our business strategy, including anticipated trends and developments in and management plans for our business and the wind industry and other markets in which we operate; future financial results, operating results, revenues, gross margin, operating expenses, profitability, products, projected costs, warranties, our ability to improve our operating margins, and capital expenditures. These forward-looking statements are often characterized by the use of words such as 'estimate,' 'expect,' 'anticipate,' 'potential,' 'project,' 'plan,' 'intend,' 'seek,' 'believe,' 'forecast,' 'foresee,' 'likely,' 'may,' 'should,' 'goal,' 'target,' 'might,' 'will,' 'could,' 'predict,' 'continue' and the negative or plural of these words and other comparable terminology. Forward-looking statements are only predictions based on our current expectations and our projections about future events. You should not place undue reliance on these forward-looking statements. We undertake no obligation to update any of these forward-looking statements for any reason. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to differ materially from those expressed or implied by these statements. These factors include, but are not limited to, the matters discussed in 'Risk Factors,' in our Annual Report on Form 10-K and other subsequent filings with the SEC. Investor Relations 480-315-8742 Investors@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
23 minutes ago
- Yahoo
HeartBeam Reports Second Quarter 2025 Results
Executing on Commercial Readiness Plans in Anticipation of FDA 510(k) Clearance for Groundbreaking 12-lead Electrocardiogram (ECG) Synthesis Software Engaged in Ongoing Productive Discussions with FDA Related to the 510(k) Application Increased Business Development Resources to Match Inbound Interest from Industry Partners Management to Host Webcast and Conference Call Today at 4:30 p.m. ET SANTA CLARA, Calif., August 13, 2025--(BUSINESS WIRE)--HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, has reported its financial and operational results for the second quarter ended June 30, 2025. Second Quarter & Subsequent 2025 Operational Highlights The Company continues to make significant progress towards commercial readiness, along with key clinical and regulatory achievements on the HeartBeam System. 12-Lead ECG Synthesis Software FDA Submission: Productive discussions are ongoing with FDA on 510(k) submission for the 12-lead ECG synthesis software in arrhythmia assessment. Timeline for FDA clearance remains firmly on track, expected by the end of the year. Presented results from pivotal VALID-ECG study in April, demonstrating that HeartBeam successfully met the clinical endpoints, with a 93.4% overall diagnostic agreement indicating that the synthesized 12-lead ECG can support diagnosis of arrhythmias in a manner consistent with standard 12-lead ECGs. Commercial Readiness Plans: Anticipate initiating commercialization upon receiving 510(k) clearance for the 12-lead ECG synthesis software. Executing on commercial readiness plans, including finalizing cardiology reader service to provide on-demand cardiologist reviews of synthesized 12-lead ECGs and triage patients. Established infrastructure for customer service, contract manufacturing, and logistics and fulfillment efforts. Proximity to FDA Clearance and commercialization is intensifying business development activity. Expanded the business development team with recognized industry expert. Other Highlights: Abstract on HeartBeam AI algorithm accepted for presentation at HRX Live 2025 in September. New international patent issued, increasing the Company's moat around its core technology; total of 21 issued patents worldwide. Received two additional industry recognitions, adding to the growing list of recent industry recognitions: Awarded the Innovation Award in Remote Cardiac Diagnostics as part of the 2025 Medical Device Network Excellence Awards for its groundbreaking ECG technology. Named finalist in 2025 Octane High Tech Awards, which recognizes innovators, entrepreneurs and technology leaders with a presence in Orange County. Cash, cash equivalents, and short-term investments totaled $5.1 million as of June 30, 2025, with net cash used in operating activities of $3.4 million for the three months ended June 30, 2025, resulting in a 23% decrease quarter-over-quarter. Management Commentary "In the quarter, we continued to engage in positive and productive discussions with the FDA on the 12-lead ECG synthesis software submission for arrhythmia assessment and we continue to anticipate clearance by the end of the year. As we have discussed, that clearance, together with our foundational clearance, will form the basis for our commercial launch," said Robert Eno, Chief Executive Officer, HeartBeam. "We continue to make significant progress with commercial readiness plans, which is positioning us for a successful launch following 510(k) clearance of our 12-lead synthesis software. "Additionally, we are seeing a marked increase in interest from industry partners as we get closer to our 12-lead ECG synthesis clearance and commercialization. We believe these players understand that HeartBeam's technology is transformative and is an ideal platform in the form of a cable free ECG that produces a synthesized 12-lead ECG output. There are multiple ways for partners to get involved in the HeartBeam ecosystem, including data and AI, companion products and services, and complementary diagnostics and treatments. "Our vision for the near future is to bring additional capabilities of a synthesized 12-lead ECG into patients' hands outside of the healthcare setting. One of the most important trends in medicine today is the movement of medical grade devices from the hospital and clinic to the patient. Accurate, connected, medical grade technologies have been shown to expand access, reduce healthcare costs and enable personalized medicine. Within cardiac diseases there is a major gap and a huge opportunity. Cardiac diseases are the leading cause of death worldwide and most cardiac events, whether arrhythmias or ischemia, happen outside of the healthcare setting. Diagnosing these events is crucial for patients and for the healthcare system and we believe that as we implement our vision, our technology will be well positioned to accomplish this," concluded Eno. Second Quarter 2025 Financial Results Research and development expenses for the second quarter of 2025 were $3.3 million, compared to $2.8 million for the second quarter of 2024. General and administrative expenses for the second quarter of 2025 were $1.7 million compared to $2.2 million for the second quarter of 2024. Net loss for the second quarter of 2025 was $5.0 million, compared to a net loss of $5.0 million for the second quarter of 2024. Net cash used in operating activities was $7.9 million for the six months ended June 30, 2025, as compared to $7.0 million for the six months ended June 30, 2024. Cash, cash equivalents, and short-term investments totaled $5.1 million as of June 30, 2025, with net cash used in operating activities of $3.4 million during the period. Second Quarter 2025 Results Conference Call HeartBeam CEO Robert Eno and CFO Tim Cruickshank will host the conference call, followed by a question-and-answer period. The conference call will be accompanied by a presentation, which can be viewed during the webcast or accessed via the investor relations section of the Company's website here. To access the call, please use the following information: Date: Wednesday, August 13, 2025 Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time) Dial-in: 1-844-826-3035 International Dial-in: 1-412-317-5195 Conference Code: 10201583 Webcast: HeartBeam Second Quarter 2025 Earnings Conference Call A telephone replay will be available approximately three hours after the call and will run through November 13, 2025, by dialing 1-844-512-2921 from the U.S., or 1-412-317-6671 from international locations, and entering replay pin number: 10201583. The replay can also be viewed through the webcast link above and the presentation utilized during the call will be available in the Company's investor relations section here. About HeartBeam, Inc. HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024. The 12-Lead ECG synthesis software is under FDA review. The Company holds over 20 issued patents related to technology enablement. For additional information, visit Forward-Looking Statements All statements in this release that are not based on historical fact are "forward-looking statements." While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our Forms 10-K, 10-Q and other reports filed with the SEC and available at We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based. Cleared Indications for Use The HeartBeam System is a portable non-invasive recorder intended to record, store, and transfer a patient's 3-Lead (in three-directions) electrocardiogram (ECG) acquired from 5 electrodes. The device is intended to be used by adult patients in either a clinical setting or at home. The device does not conduct cardiac analysis and can be used with an ECG Viewer software system for manual interpretation of non-life-threatening arrhythmias by a physician or healthcare professional. For full safety information, see the full Instructions for Use or Clinician Portal Manual. HEARTBEAM, INC. Condensed Balance Sheets (Unaudited) (In thousands, except share data) June 30, 2025 December 31, 2024 Assets Current Assets: Cash and cash equivalents $ 3,256 $ 2,377 Short-term investments (Note 3) 1,797 — Prepaid expenses and other current assets 308 393 Total Current Assets 5,361 2,770 Property and equipment, net 564 450 Other assets 56 56 Total Assets $ 5,981 $ 3,276 Liabilities and Stockholders' Equity Current Liabilities: Accounts payable (includes related party $0 and $5, respectively) $ 814 $ 531 Accrued expenses (includes related party $5 and $0, respectively) 985 1,091 Total Current Liabilities 1,799 1,622 Total Liabilities 1,799 1,622 Commitments (Note 7) Stockholders' Equity Preferred stock - $0.0001 par value; 10,000,000 authorized; 0 shares outstanding at June 30, 2025 and December 31, 2024 — Common stock - $0.0001 par value 100,000,000 shares authorized; 34,020,340 and 26,960,901 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively 4 3 Additional paid in capital 70,909 57,924 Accumulated deficit (66,731 ) (56,273 ) Total Stockholders' Equity 4,182 1,654 Total Liabilities and Stockholders' Equity $ 5,981 $ 3,276 HEARTBEAM, INC. Condensed Statements of Operations (Unaudited) (In thousands, except share and per share data) Three months ended June 30, Six months ended June 30, 2025 2024 2025 2024 Operating Expenses: General and administrative $ 1,711 $ 2,246 $ 3,720 $ 4,602 Research and development 3,326 2,844 6,818 5,272 Total operating expenses 5,037 5,090 10,538 9,874 Loss from operations (5,037 ) (5,090 ) (10,538 ) (9,874 ) Other Income and (Expense) Interest income 63 134 80 312 Total other income 63 134 80 312 Loss before provision for income taxes (4,974 ) (4,956 ) (10,458 ) (9,562 ) Income tax provision — — — — Net Loss $ (4,974 ) $ (4,956 ) $ (10,458 ) $ (9,562 ) Net loss per share, basic and diluted $ (0.15 ) $ (0.19 ) $ (0.32 ) $ (0.36 ) Weighted average common shares outstanding, basic and diluted 33,834,950 26,566,832 32,184,025 26,538,863 HEARTBEAM, INC. Condensed Statements of Cash Flows (Unaudited) (In thousands) Six months ended June 30, 2025 2024 Cash Flows From Operating Activities Net loss $ (10,458 ) $ (9,562 ) Adjustments to reconcile net loss to net cash used in operating activities Depreciation 15 — Stock based compensation expense 2,286 2,247 Changes in operating assets and liabilities: Prepaid expenses and other current assets 85 92 Accounts payable and accrued expenses 150 210 Net cash used in operating activities (7,922 ) (7,013 ) Cash Flows From Investing Activities Purchase of property and equipment (102 ) (98 ) Purchase of short-term investments (3,760 ) — Maturities of short-term investments 1,963 — Net cash used in investing activities (1,899 ) (98 ) Cash Flows From Financing Activities Proceeds from sale of equity, net of issuance costs 10,250 — Proceeds from sale of equity under ATM, net of issuance costs 450 76 Proceeds from exercise of stock options — 8 Net cash provided by financing activities 10,700 84 Net increase (decrease) in cash and restricted cash 879 (7,027 ) Cash, cash equivalents and restricted cash – Beginning of period 2,433 16,239 Cash, cash equivalents and restricted cash – Ending of period $ 3,312 $ 9,212 Reconciliation of cash, cash equivalents and restricted cash: Cash and cash equivalents $ 3,256 $ 9,157 Restricted cash (included in other assets) 56 55 Total cash, cash equivalents and restricted cash $ 3,312 $ 9,212 Supplemental Disclosures of Cash Flow Information: Purchase of property and equipment in accounts payable $ 27 $ 16 Taxes paid $ — $ — View source version on Contacts Investor Relations Contact: Chris Tyson Executive Vice PresidentMZ North AmericaDirect: 949-491-8235BEAT@ Media Contact: media@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Stock market today: Dow, S&P 500, Nasdaq futures trade flat with PPI looming amid rate-cut fervor
US stock futures hovered around the flatline as Wall Street awaited another pulse check on inflation after Tuesday's tepid figures sent rate-cut bets and markets soaring. Futures attached to the Dow Jones Industrial Average (YM=F), the benchmark S&P 500 (ES=F), and the tech-heavy Nasdaq 100 (NQ=F) mostly traded flat. Stocks extended their rally Wednesday, pushing the S&P 500 and Nasdaq to consecutive record highs. Bitcoin got a boost from mounting rate-cut bets too, reaching a new record high on Wednesday evening. Euphoria over a possible September rate cut swept Wall Street on Tuesday after July's Consumer Price Index report showed inflation rose as expected, but not dramatically. Traders have now fully priced in a rate cut at the Fed's next meeting even as some Fed policymakers continue to urge patience. On Thursday, investors will be eager to see if July's Producer Price Index (PPI) report falls in line with the CPI data that has boosted sentiment this week. Sign in to access your portfolio
